794 related articles for article (PubMed ID: 27062198)
21. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
25. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
[TBL] [Abstract][Full Text] [Related]
26. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
[TBL] [Abstract][Full Text] [Related]
27. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
Canzoneri JC; Chen PC; Oyelere AK
Bioorg Med Chem Lett; 2009 Dec; 19(23):6588-90. PubMed ID: 19854643
[TBL] [Abstract][Full Text] [Related]
29. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
[TBL] [Abstract][Full Text] [Related]
30. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
32. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
[TBL] [Abstract][Full Text] [Related]
33. Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition.
King K; Hauser AT; Melesina J; Sippl W; Jung M
Molecules; 2018 Feb; 23(2):. PubMed ID: 29393896
[TBL] [Abstract][Full Text] [Related]
34. The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker.
Yang F; Zhao N; Hu Y; Jiang CS; Zhang H
Chem Biodivers; 2020 Jan; 17(1):e1900427. PubMed ID: 31793143
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
36. Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors.
Singh RK; Mandal T; Balasubramanian N; Cook G; Srivastava DK
Anal Biochem; 2011 Jan; 408(2):309-15. PubMed ID: 20816742
[TBL] [Abstract][Full Text] [Related]
37. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
[TBL] [Abstract][Full Text] [Related]
39. A cyclodextrin-capped histone deacetylase inhibitor.
Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
[TBL] [Abstract][Full Text] [Related]
40. Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
Taddei M; Cini E; Giannotti L; Giannini G; Battistuzzi G; Vignola D; Vesci L; Cabri W
Bioorg Med Chem Lett; 2014 Jan; 24(1):61-4. PubMed ID: 24345446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
